Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helius Medical Technologies ( (HSDT) ) has shared an update.
On July 7, 2025, Helius Medical Technologies announced that it has regained compliance with Nasdaq’s equity and minimum bid price requirements, ensuring its continued listing on The Nasdaq Capital Market. The company will be under a mandatory monitoring period until July 7, 2026, during which any further non-compliance could lead to a delisting determination without the opportunity for a compliance plan or additional time.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies faces significant financial and operational challenges, reflected in its poor financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further underscore the stock’s unattractiveness. Although the recent fundraising effort to meet Nasdaq compliance is a positive development, it does not substantially improve the company’s financial outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies, Inc. operates in the medical technology industry, focusing on developing non-invasive platform technologies that amplify the brain’s ability to heal itself, primarily targeting neurological wellness.
Average Trading Volume: 144,023
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.39M
Find detailed analytics on HSDT stock on TipRanks’ Stock Analysis page.